汇宇制药：全资子公司获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Sichuan Huiyu Pharmaceutical Co., Ltd. announced the approval of a clinical trial for its innovative chemical drug HYP-6589, which will be used in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [1][1][1] Group 2 - Sichuan Huiyu Pharmaceutical's wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration [1][1][1] - The approval signifies a significant step in the development of HYP-6589, indicating the company's commitment to advancing cancer treatment options [1][1][1]